Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jissy Thomas"'
Autor:
Kaiming Wang, Erik Youngson, Jeffrey A. Bakal, Jissy Thomas, Finlay A. McAlister, Gavin Y. Oudit
Publikováno v:
ESC Heart Failure, Vol 8, Iss 4, Pp 3106-3118 (2021)
Abstract Aims This study aims to assess long‐term changes in left ventricular ejection fraction (LVEF) together with echocardiographic markers of cardiac remodelling and their association with prognosis and patient‐reported quality of life (QoL).
Externí odkaz:
https://doaj.org/article/359a933c4a1140fbafdf333f278ac98a
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 6 (2018)
Resistant hypertension remains an important cause of heart failure. In this article, we describe a case of resistant hypertension in a 63-year-old woman leading to heart failure and marked morbidity. Her clinical course was characterized by chronic p
Externí odkaz:
https://doaj.org/article/f75006df5f8b422f85ffcabf9e27e40d
Autor:
Jissy Thomas, Arthur A. Qi, Gavin Y. Oudit, Finlay A. McAlister, Kaiming Wang, Anish Nikhanj, Quynh Nguyen, Erik Youngson
Publikováno v:
European Heart Journal. 41
Background Recovery or improvement in LVEF is observed in many HFrEF patients following optimal medical management and device therapies, but whether this reflects true myocardial recovery remains controversial and the significance of LVEF decompensat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::599ae1d7dcde0954990a0b63067c50d3
https://doi.org/10.1093/ehjci/ehaa946.0929
https://doi.org/10.1093/ehjci/ehaa946.0929
Autor:
Gavin Y. Oudit, Jissy Thomas, Miriam Shanks, David Ian Paterson, Amy X. Du, Finlay A. McAlister, Mikael Hanninen, Justin A. Ezekowitz, Cynthia M. Westerhout
Publikováno v:
Journal of cardiovascular pharmacology. 73(3)
Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto, Quebec, Canada) in a nonclinical trial population. This study was conducted to evaluate the use and tolerability of sacubitril/valsartan in patients followed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ade788a8e660e090863761458b640f1a
https://pubmed.ncbi.nlm.nih.gov/30540684
https://pubmed.ncbi.nlm.nih.gov/30540684
Autor:
Marko Poglitsch, Brian H. Rowe, Haran Yogasundaram, Gavin Y. Oudit, Ratnadeep Basu, Jissy Thomas
Publikováno v:
Journal of the American College of Cardiology. 69(7)
Background The renin-angiotensin system (RAS) is activated in heart failure (HF) and inhibition of RAS is a mainstay therapy for HF. Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin 1–7 (Ang-[1–7]), are important negative regul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::758f4d5667da795f1d1d70b2c41d7632
https://pubmed.ncbi.nlm.nih.gov/28619205
https://pubmed.ncbi.nlm.nih.gov/28619205
Publikováno v:
Heart & Lung. 39:217-225
Background Nearly 75% of critically ill patients develop anemia in the intensive care unit (ICU). Anemia can be treated with red blood cell (RBC) transfusions, although evidence suggests that lower hemoglobin levels are tolerated in the critically il
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c331b5a7f3fc694d00a8fd75f0b442a
https://doi.org/10.1016/j.hrtlng.2009.07.002
https://doi.org/10.1016/j.hrtlng.2009.07.002